The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Published version of a preprint
Abstract
Wee1 is a tyrosine kinase that phosphorylates and inactivates CDC2 and is involved in G2 checkpoint signaling. Because p53 is a key regulator in the G1 checkpoint, p53-deficient tumors rely only on the G2 checkpoint after DNA damage. Hence, such tumors are selectively sensitized to DNA-damaging agents by Wee1 inhibition. Here, we report the discovery of a potent and selective small-molecule inhibitor of Wee1 kinase, MK-1775. This compound inhibits phosphorylation of CDC2 at Tyr15 (CDC2Y15), a direct substrate of Wee1 kinase in cells. MK-1775 abrogates G2 DNA damage checkpoint, leading to apoptosis in combination with DNA-damaging chemotherapeutic agents such as gemcitabine, carboplatin, and cisplatin selectively in p53-deficient cells. In vivo, MK-1775 potentiates tumor growth inhibition by these agents, and cotreatment does not significantly increase toxicity. The enhancement of antitumor effect by MK-1775 was well correlated with inhibition of CDC2Y15 phosphorylation in tumor tissue and skin hair follicles. Our data indicate that Wee1 inhibition provides a new approach for treatment of multiple human malignancies. [Mol Cancer Ther 2009;8(11):2992–3000]
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K., & Linn, S. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073723 · Cited by 3,317
Inactivation of the p34 cdc2 -Cyclin B Complex by the Human WEE1 Tyrosine Kinase
Parker, L. L., & Piwnica-Worms, H. (1992) · Science · doi:10.1126/science.1384126 · Cited by 716
Mueller, P. R., Coleman, T. R., Kumagai, A., & Dunphy, W. G. (1995) · Science · doi:10.1126/science.270.5233.86 · Cited by 695
Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15.
McGowan, C. H., & Russell, P. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05633.x · Cited by 493
Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle.
Watanabe, N., Broome, M., & Hunter, T. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07180.x · Cited by 450
Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation
O'Connell, M. J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.3.545 · Cited by 398
Targeting the checkpoint kinases: chemosensitization versus chemoprotection
Zhou, B.-B. S., & Bartek, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1296 · Cited by 391
Cell cycle checkpoints and their inactivation in human cancer
Molinari, M. (2000) · Cell Proliferation · doi:10.1046/j.1365-2184.2000.00191.x · Cited by 388
G2 checkpoint abrogators as anticancer drugs
Kawabe, T. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.513.3.4 · Cited by 377
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Metadata
- Authors
- Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., Itadani, H., Takahashi-Suzuki, I., Fukasawa, K., Oki, H., Nambu, T., Jiang, J., Sakai, T., Arakawa, H., Sakamoto, T., Sagara, T., Yoshizumi, T., Mizuarai, S., & Kotani, H.
- Affiliations
- Departments of 1Oncology, 2Pharmacology, and 3Chemistry, Banyu Tsukuba Research Institute, Merck Research Laboratories, Tsukuba, Japan
- Venue
- Molecular Cancer Therapeutics
- Published
- 2009-11-01
- Volume
- 8
- Issue
- 11
- Pages
- 2992-3000
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2096293110
- Cited by
- 540
- References
- 31
- Citations by year
- 2026: 27 · 2025: 24 · 2024: 33 · 2023: 63 · 2022: 37 · 2021: 39 · 2020: 47 · 2019: 34 · 2018: 41 · 2017: 39 · 2016: 34 · 2015: 34 · 2014: 22 · 2013: 27 · 2012: 22
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- WEE1, MK-1775, p53-deficient tumors, G2 checkpoint, Cdc2 phosphorylation, DNA-damaging agents, chemosensitization, gemcitabine, carboplatin, cisplatin, apoptosis, small-molecule kinase inhibitors, combination chemotherapy
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, DNA Damage, Drug Synergism, Flow Cytometry, HeLa Cells, Humans, Neoplasms, Nuclear Proteins, Phosphorylation, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Pyrimidinones, Rats, Inbred F344, Rats, Nude, Tumor Suppressor Protein p53, CDC2 Protein Kinase, Apoptosis, Cell Cycle Proteins, Cyclin-Dependent Kinases, Cyclin B, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. https://app.cochat.ai/papers/10.1158/1535-7163.mct-09-0463
- The paper
- Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., Itadani, H., Takahashi-Suzuki, I., Fukasawa, K., Oki, H., Nambu, T., Jiang, J., Sakai, T., Arakawa, H., Sakamoto, T., . . . Kotani, H. (2009). Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-09-0463
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.